Business Wire

Nine-in-10 Legal Leaders Brace for Sharp Rise in Online IP Infringement as AI Accelerates Attacks

28.10.2025 14:00:00 CET | Business Wire | Press Release

Share

Nine-in-10 (91%) senior legal professionals are concerned about the threat of online intellectual property (IP) infringement, according to new research commissioned by CSC, the leading provider of global business administration and compliance solutions.While 85% report an increase in IP infringements at their firms over the past 12 months, 90% are expecting more in the year ahead with 89% predicting continued escalation over the next three years.

While the most common forms of IP infringement are rated as counterfeiting, trademark abuse, and brand impersonation, all of which can erode consumer trust and inflict long-term financial and reputation damage, the threat of artificial intelligence (AI) looms large—88% say AI-enabled systems are driving an increase in infringement activity, and 93% are concerned that AI-generated fake assets such as logos, images, and content could materially harm their business.

The findings come from CSC’s latest study1, “IP Frontiers Report 2025: Proactive Security Against IP Infringement,” that surveyed 300 senior legal, compliance, and IP professionals in Europe including the U.K., Asia Pacific, and North America.

“With how much commerce and communication takes place online, a brand’s reputation is built on its online presence and guarding it is a responsibility companies should take seriously,” says Ihab Shraim, chief technology officer, CSC’s Digital Brand Services division. “There’s a massive influx of sophisticated threat vectors targeting corporations, and the easiest targets are domain names and IP. In the past, fraudsters would send hundreds of thousands of phishing emails hoping that 2% or 3% would respond. Today, fraudulent activity is more targeted and comes with a much higher rate of success, particularly as AI quickly becomes a major accelerant.”

CSC’s study also finds that fake domain names are often the first step in large-scale infringement campaigns. Although 76% of organizations have a domain management strategy in place, only 16% of legal teams have total visibility into how their portfolios are managed—creating oversights that leave brands exposed to fraud, phishing, and impersonation.

Many firms are adapting to these threats, with partnerships with third-party specialists playing a growing role. Two-thirds (67%) of respondents say they expect significant increases in brand protection and IP enforcement budgets over the next three years, and more than half (56%) say they already outsource some of their monitoring efforts—a trend expected to rise as organizations seek more advanced tools and faster takedown mechanisms.

“The ability for fraudsters to carry out IP infringements is iterating at such a pace that it will be to everyone’s benefit to be more aware of what’s happening, to be more security minded, and to foster stronger collaboration among internal teams and external specialists,” says Ian McConnel, chief legal officer at CSC. “Like it or not, domain management is a key part of cybersecurity strategies, not just protecting your crown jewel domain names.

“Reactive defenses are no longer enough. Fraudsters exploit low-cost, fast-moving tools to impersonate brands at scale. As AI adoption expands the avenues for infringement, companies that adopt proactive, multi-layered protection—integrating legal, IT, and security teams, and partnering with trusted corporate registrars—will be best positioned to safeguard brand reputation in the AI era.”

About CSC

CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands (Interbrand®) with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSecSM platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscglobal.com.

1CSC, in partnership with Pure Profile, surveyed 300 senior legal professionals, including general counsels, chief legal officers, and chief compliance officers practicing in Europe, the U.K., North America, and Asia Pacific, via an online methodology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028810730/en/

Contacts

CDR
Hassan Ali | Thomas Dalton
cscteam@cdrconsultancy.com

CSC
Laura Crozier
PR Manager
laura.crozier@cscglobal.com
CSC News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fpress%2F&esheet=54343481&newsitemid=20251028810730&lan=en-US&anc
hor=CSC+News+Room&index=2&md5=fe0ba196f519017db8cb595781871d04

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye